Clinical and Biological Predictors of Outcome Following Relapse of Chronic Myeloid Leukemia after Allogeneic Stem Cell Transplantation

[1]  J. Goldman.  The significance of BCR-ABL transcripts after allogeneic stem cell transplantation for chronic myeloid leukemia. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[2]  G. Fahle,et al.  CMV reactivation is associated with a lower incidence of relapse after allo-SCT for CML , 2013, Bone Marrow Transplantation.

[3]  J. Goldman,et al.  Three decades of transplantation for chronic myeloid leukemia: what have we learned? , 2011, Blood.

[4]  B. Druker,et al.  Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. , 2011, The Journal of clinical investigation.

[5]  J. Melo,et al.  In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib. , 2010, Blood.

[6]  J. Klein,et al.  Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Silver.  The blast phase of chronic myeloid leukaemia. , 2009, Best practice & research. Clinical haematology.

[8]  A. Barrett,et al.  The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. , 2009, Blood.

[9]  A. Barrett.  Understanding and harnessing the graft‐versus‐leukaemia effect , 2008, British journal of haematology.

[10]  Francisco Cervantes,et al.  Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. , 2006, Blood.

[11]  H. Kantarjian,et al.  Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. , 2006, Blood.

[12]  D. Marin,et al.  Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy. , 2006, Blood.

[13]  K. Rezvani,et al.  Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia. , 2006, Blood.

[14]  A. Barrett,et al.  Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation , 2005, Bone Marrow Transplantation.

[15]  C. Eaves,et al.  Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease , 2005, Leukemia.

[16]  Laurie E Ailles,et al.  Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. , 2004, The New England journal of medicine.

[17]  J. Ritz,et al.  Extended Follow-up of Patients Treated with Imatinib Mesylate (Gleevec) for Chronic Myelogenous Leukemia Relapse after Allogeneic Transplantation , 2004, Clinical Cancer Research.

[18]  H. Cavé,et al.  Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program , 2003, Leukemia.

[19]  F. Watzinger,et al.  Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer program , 2003, Leukemia.

[20]  J. Melo,et al.  Chronic myeloid leukemia--advances in biology and new approaches to treatment. , 2003, The New England journal of medicine.

[21]  W. Siegert,et al.  Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia , 2003, Leukemia.

[22]  H. Gschaidmeier,et al.  Current results on the use of imatinib mesylate in patients with relapsed Philadelphia chromosome positive leukemia after allogeneic or syngeneic hematopoietic stem cell transplantation. , 2003, The Keio journal of medicine.

[23]  N. Young,et al.  Cyclosporine is required to prevent severe acute GVHD following T-cell-depleted peripheral blood stem cell transplantation , 2003, Bone Marrow Transplantation.

[24]  H. Kantarjian,et al.  Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. , 2002, Blood.

[25]  J. Goldman,et al.  Relapse of chronic myeloid leukaemia 14 years after allogeneic bone marrow transplantation , 1999, Bone Marrow Transplantation.

[26]  Schaap,et al.  Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real‐time quantitative RT‐PCR , 1998, British journal of haematology.

[27]  C. Dunbar,et al.  Long-term culture of chronic myelogenous leukemia marrow cells on stem cell factor-deficient stroma favors benign progenitors. , 1995, Blood.

[28]  J. Goldman,et al.  Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. , 1994, Blood.

[29]  R. Marcus,et al.  Bone marrow transplantation for patients with chronic myeloid leukemia. , 1986, The New England journal of medicine.

[30]  P. Neiman,et al.  TREATMENT OF CHRONIC GRANULOCYTIC LEUKAEMIA IN CHRONIC PHASE BY ALLOGENEIC MARROW TRANSPLANTATION , 1982, The Lancet.

[31]  J.,et al.  The New England Journal of Medicine , 2012 .

[32]  O. Haas,et al.  Improved outcome in patients with chronic myelogenous leukemia after allogeneic hematopoietic stem cell transplantation over the past 25 years: a single-center experience. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[33]  J. Melo,et al.  Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML. , 2006, Blood.

[34]  S. Lee,et al.  Cytogenetic clonal evolution alone in CML relapse post-transplantation does not adversely affect response to imatinib mesylate treatment , 2004, Bone Marrow Transplantation.